CRISPR-Cas12-based detection of SARS-CoV-2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32300245.
- Also identified by DOI 10.1038/s41587-020-0513-4 and PMC identifier 9107629.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.
Medical subject headings
- Betacoronavirus
- CRISPR-Cas Systems
- Clinical Laboratory Techniques
- Nucleic Acid Amplification Techniques